Literature DB >> 24706695

Development of an active site peptide analog of α-fetoprotein that prevents breast cancer.

Herbert I Jacobson1, Thomas T Andersen2, James A Bennett3.   

Abstract

Epidemiologic studies associate elevated maternal serum levels of α-fetoprotein (AFP) with reduced breast cancer risk for parous women. Laboratory studies demonstrate direct anti-breast cancer activity of AFP. Here, we review the development of a small cyclic peptide that is an active site analog of AFP, referred to as AFPep, which is composed exclusively of amino acids, is orally active, has no discernable toxicity, and is effective for the treatment and prevention of breast cancer in animal models. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24706695     DOI: 10.1158/1940-6207.CAPR-13-0405

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  4 in total

1.  Peptide ligands for targeting the extracellular domain of EGFR: Comparison between linear and cyclic peptides.

Authors:  Tyrslai M Williams; Rushikesh Sable; Sitanshu Singh; Maria Graca H Vicente; Seetharama D Jois
Journal:  Chem Biol Drug Des       Date:  2017-11-16       Impact factor: 2.817

2.  Distribution bias analysis of germline and somatic single-nucleotide variations that impact protein functional site and neighboring amino acids.

Authors:  Yang Pan; Cheng Yan; Yu Hu; Yu Fan; Qing Pan; Quan Wan; John Torcivia-Rodriguez; Raja Mazumder
Journal:  Sci Rep       Date:  2017-02-08       Impact factor: 4.379

3.  Parity association with clinicopathological factors in invasive breast cancer: a retrospective analysis.

Authors:  Sandi Shen; Shizhen Zhong; Gaofang Xiao; Haibo Zhou; Wenhua Huang
Journal:  Onco Targets Ther       Date:  2017-01-21       Impact factor: 4.147

4.  Primary neuroendocrine carcinoma of the breast with markedly elevated alpha-fetoprotein: a case report.

Authors:  Jia Wang; Xichen Wang; Wenlong Du; Yuanxian Guo; Xiaoping Yang; Jiebin Pan; Lanning Yin
Journal:  Transl Cancer Res       Date:  2021-05       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.